VivaGel® BV Launch(es)

...... and after almost 3 years from the Europe approval and 6 months from the Aust / NZ approval and countless official assurances, there is still not one tube of VivaGel^® BV that is available in the 30 countries that we are sitting on approvals from ??? Speaks volumes

Melbourne, Australia 24; September 2015:
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has received, overnight, marketing approval in the European Union (EU) for VivaGel^® BV for the treatment and rapid relief of bacterial vaginosis (BV) including symptoms.

The approval allows for the marketing of VivaGel^® BV in the European Economic Area (EEA), which includes the 28 countries of the EU plus the European Free Trade Association (EFTA) countries, providing access to a population of more than 260 million women.  In addition, the EU approval will be used as the basis for obtaining what is expected to be relatively rapid regulatory and marketing approvals for VivaGel^® BV in a number of other countries that formally recognise the EU approval.

Melbourne, Australia; 25 October 2017:
“With the upcoming launch of VivaGel® BV, Australian clinicians and pharmacists will soon be able to recommend this novel non-antibiotic treatment for this common and problematic condition. For Starpharma, it is particularly exciting to launch this Australian innovation into the local market. Aspen is an ideal partner for VivaGel® BV in Australia with a proven track record in women’s health.”


Melbourne, Australia; 21 December 2017:
In Australia VivaGel® BV is licensed to Aspen Pharmacare, who will launch the product in the near future.


Melbourne, Australia; 29 November 2017:
" Women suffering from BV are finally on the cusp of being able to access a safe and effective non-antibiotic solution for this very troubling condition"  - Chairman's address


Melbourne, Australia; 19 February 2018:
Launch plans for VivaGel® BV are well advanced and the product is expected to be available in pharmacies shortly.